Search results for "Treatment evaluation"
showing 4 items of 4 documents
Replacement therapy for bleeding episodes in factor VII deficiency: A prospective evaluation
2013
Patients with inherited factor VII (FVII) deficiency display different clinical phenotypes requiring ad hoc management. This study evaluated treatments for spontaneous and traumatic bleeding using data from the Seven Treatment Evaluation Registry (STER). One-hundred one bleeds were analysed in 75 patients (41 females; FVII coagulant activity <1-20%). Bleeds were grouped as haemarthroses (n=30), muscle/subcutaneous haematomas (n=16), epistaxis (n=12), gum bleeding (n=13), menorrhagia (n=16), central nervous system (CNS; n=9), gastrointestinal (GI; n=2) and other (n=3). Of 93 evaluable episodes, 76 were treated with recombinant, activated FVII (rFVIIa), eight with fresh frozen plasma (FFP), s…
Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)
2013
WOS: 000319897700018
A fully automatic 2D segmentation method for uterine fibroid in MRgFUS treatment evaluation
2015
PurposeMagnetic Resonance guided Focused UltraSound (MRgFUS) represents a non-invasive surgical approach that uses thermal ablation to treat uterine fibroids. After the MRgFUS treatment, an operator must manually segment the treated fibroid areas to evaluate the NonPerfused Volume (NPV). This manual approach is operator-dependent, introducing issues of result reproducibility, which could lead to errors in the subsequent follow-up phase. Moreover, manual segmentation is time-consuming, and can have a negative impact on the optimization of both machine-time and operator-time. MethodTo address these issues, in this paper a novel fully automatic method based on the unsupervised Fuzzy C-Means cl…
A Semi-automatic Multi-seed Region-Growing Approach for Uterine Fibroids Segmentation in MRgFUS Treatment
2013
Fibroids are benign tumors growing in the uterus. Most of fibroids do not require treatment unless they are causing symptoms. Traditional surgery treatments, like myomectomy and hysterectomy, are very invasive therapeutic approaches which not always preserves reproductive potential of the woman. MRgFUS, performed with Insightec ExAblate 2100 equipment, is a new and noninvasive technique for uterine fibroids treatment, not requiring hospitalization and recovery time for patients. An initial assessment of MRgFUS treatment is made by computing the ablated volume of uterine fibroid. In this paper a semi-automatic approach, based on region-growing segmentation technique, is proposed. The impleme…